Peel Hunt Reiterates Buy Rating for Circassia Pharmaceuticals (CIR)

Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Peel Hunt in a report released on Tuesday.

CIR has been the subject of several other research reports. Numis Securities reaffirmed a “buy” rating and set a GBX 140 ($1.83) target price on shares of Circassia Pharmaceuticals in a research note on Thursday, September 27th. Royal Bank of Canada decreased their target price on Circassia Pharmaceuticals from GBX 86 ($1.12) to GBX 81 ($1.06) and set a “sector performer” rating for the company in a research note on Wednesday, October 17th.

Shares of CIR stock opened at GBX 59 ($0.77) on Tuesday.

About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.

Featured Article: Why do companies issue stock splits?

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply